Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.54 |
| ▸ | TAF1 | P21675 | 2/20 | 0.54 |
| ▸ | PLK1 | P53350 | 15/20 | 0.53 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.53 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672321 | 0.94 | PLK1 (0.58) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL4081000 | 0.92 | BRD4 (0.65) | BRD4TAF1PLK1BRDTRAD52 | |
| SCHEMBL4075904 | 0.89 | BRD4 (0.55) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL3666157 | 0.87 | PLK1 (0.53) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL2396243 | 0.87 | PLK1 (0.70) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL2396540 | 0.87 | PLK1 (0.70) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL2396238 | 0.87 | PLK1 (0.70) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL2398292 | 0.87 | PLK1 (0.59) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL4079491 | 0.86 | PLK1 (0.63) | BRD4TAF1PLK1PLK3PLK2 | |
| SCHEMBL4080758 | 0.85 | BRD4 (0.46) | BRD4TAF1PLK1PLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | BRD4 123/4885TAF1 3573/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.